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Introduction: Lewy body and Alzheimer-type pathologies often co-exist. Several studies suggest a synergistic
relationship between amyloid-β (Aβ) and α-synuclein (α-syn) accumulation. We have explored the relationship
between Aβ accumulation and the phosphorylation of α-syn at serine-129 (pSer129 α-syn), in post-mortem human
brain tissue and in SH-SY5Y neuroblastoma cells transfected to overexpress human α-syn.
Methods: We measured levels of Aβ40, Aβ42, α-syn and pSer129 α-syn by sandwich enzyme-linked immunosorbent
assay, in soluble and insoluble fractions of midfrontal, cingulate and parahippocampal cortex and thalamus, from cases
of Parkinson’s disease (PD) with (PDD; n = 12) and without dementia (PDND; n = 23), dementia with Lewy bodies
(DLB; n = 10) and age-matched controls (n = 17). We also examined the relationship of these measurements to
cognitive decline, as measured by time-to-dementia and the mini-mental state examination (MMSE) score in the
PD patients, and to Braak tangle stage.
Results: In most brain regions, the concentration of insoluble pSer129 α-syn correlated positively, and soluble
pSer129 α-syn negatively, with the levels of soluble and insoluble Aβ. Insoluble pSer129 α-syn also correlated
positively with Braak stage. In most regions, the levels of insoluble and soluble Aβ and the proportion of insoluble
α-syn that was phosphorylated at Ser129 were significantly higher in the PD and DLB groups than the controls, and
higher in the PDD and DLB groups than the PDND brains. In PD, the MMSE score correlated negatively with the level
of insoluble pSer129 α-syn. Exposure of SH-SY5Y cells to aggregated Aβ42 significantly increased the proportion of
α-syn that was phosphorylated at Ser129 (aggregated Aβ40 exposure had a smaller, non-significant effect).
Conclusions: Together, these data show that the concentration of pSer129 α-syn in brain tissue homogenates
is directly related to the level of Aβ and Braak tangle stage, and predicts cognitive status in Lewy body diseases.Introduction
Alzheimer’s disease (AD), Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) are the most common
age-related neurodegenerative diseases and together ac-
count for 80% to 90% of patients with dementia [1,2].
The pathological hallmarks of AD are extracellular accu-
mulations of amyloid-β (Aβ) as plaques and intracellular
aggregates of hyperphosphorylated tau that form neuro-
fibrillary tangles and neuropil threads. The pathological
hallmarks of PD and DLB are Lewy bodies and Lewy* Correspondence: seth.love@bris.ac.uk
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unless otherwise stated.neurites, composed of α-synuclein (α-syn) [3-5]. Although
these defining abnormalities are characteristic and dis-
tinct, many dementia cases have mixed pathology: a large
proportion of AD patients (>50%) has additional Lewy
body pathology in addition to plaques and tangles [6-16].
In Parkinson’s disease with dementia (PDD) and DLB ap-
proximately 40% of cases have significant numbers of Aβ
plaques and neurofibrillary tangles [17]. Patients with
mixed pathology tend to pursue a more aggressive dis-
ease course [18], with more pronounced cognitive dys-
function than in patients with pure AD [19-24].
In PD and DLB, the number of cortical α-syn aggregates
is significantly higher in patients who have Aβ plaques in
the cortex [25,26] and α-syn accumulates within someLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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mice expressing both Aβ and α-syn had more Lewy
body pathology and more severe deficits in learning and
memory than did mice expressing α-syn alone [28]. These
studies suggest a synergistic relationship between Aβ and
α-syn. However, the reasons for the frequent pathological
overlap between AD and Lewy body diseases are poorly
understood. A recent meta-analysis of genome-wide asso-
ciation studies of AD and PD did not detect any gene loci
that increased the risk of both diseases and concluded that
the pathological overlap is likely to result from processes
downstream of the susceptibility genes for the individual
diseases [29]. α-syn can induce the hyperphosphorylation
of tau through the activation of protein kinase A [30] and
glycogen synthase kinase 3β [31,32] and, thereby, promote
the formation of neurofibrillary tangles. However, it is
noteworthy that the most frequent form of pathological
overlap between Lewy body diseases and AD is the pres-
ence of increased numbers of Aβ plaques in PDD and
DLB [25,33], with limited formation of tangles and the in-
teractions between α-syn and Aβ were, therefore, the pri-
mary focus of this study.
The predominant modification of α-syn in Lewy body dis-
eases is phosphorylation at Ser129 [34,35]. Approximately
90% of α-syn within Lewy bodies and neurites is phosphory-
lated at Ser129, compared to 4% in the normal brain [35].
The precise role of α-syn phosphorylation at Ser129 remains
unclear: most [36-39], but not all, studies [40-42] suggest
that phosphorylation mediates the aggregation and neuro-
toxicity of α-syn. Irrespective of whether these changes
precede the development of Lewy bodies or occur at a
later stage, it is well established that pSer129 α-syn levels
correlate with disease severity [43-45]. Obi et al. [44]
found, that in DLB cases with AD pathology, pSer129
α-syn levels correlated strongly with parenchymal Aβ
load (as assessed by immunohistochemistry). The aim
of our study was to explore this relationship further, in
multiple regions of brain from Parkinson’s disease without
dementia (PDND), PDD and DLB patients and age-matched
controls, by measuring the concentrations of the twoTable 1 Control, Parkinson’s disease non-dementia (PDND), P
Lewy bodies (DLB) cases: demographic and clinical data
Control (n = 17)
Mean age at onset (years) ± SD N/A
Mean age at death (years) ± SD 79.2 ± 8.7
Mean disease duration (years) ± SD N/A
Gender (%) 3 (18) female
Mean post-mortem delay (hours) ± SD 37.0 ± 16.6
Mean time to dementia (years) ± SD N/A
Median Braak tangle stage (range) II (0 to III)
N/A, not available; n, number; SD, standard deviation.major forms of soluble and insoluble Aβ (Aβ40, Aβ42)
by sandwich ELISA, as previously [46-49], and of soluble
and insoluble α-syn (both total and pSer129 α-syn) also by
ELISA. In PD patients we also analyzed the relationship
between Aβ, total α-syn, pSer129 α-syn and ante-mortem
cognitive function, as indicated by mini-mental state
examination (MMSE) scores. Lastly, in SH-SY5Y cells that
stably expressed high levels of endogenous α-syn, we
assessed the direct influence of different forms of Aβ on
the phosphorylation of α-syn at Ser129 in vitro.
Methods
Case selection
We studied 35 cases of PD (23 PDND and 12 PDD)
from the Queen Square Brain Bank (QSBB) for Neuro-
logical Disorders, UCL Institute of Neurology, London,
and 10 cases of DLB and 17 age-matched controls from
the South West Dementia Brain Bank (SWDBB), Univer-
sity of Bristol (Table 1). Protocols for brain banking at
the QSBB were approved by the London Multi-Centre
Research Ethics Committee (REC reference 08/H0718/
54 + 5) and written consent for the use of brain tissue
and for access to the medical record for research was
obtained from all cases. The South West Dementia Brain
Bank had ethical approval from the North Somerset and
South Bristol Research Ethics Committee (REC reference
08/H0106/28).
All disease cases were diagnosed using widely accepted
neuropathological criteria [50,51]. Cases were excluded from
the study if they had a neuropathological diagnosis of AD
(that is, if histology showed AD neuropathological change
that was considered a sufficient explanation for dementia
according to the National Institute on Aging-Alzheimer’s
Association guidelines for the neuropathological assess-
ment of AD [51] or any other neurodegenerative disease
apart from PD or DLB. They were also excluded if neuro-
histology revealed severe cerebral amyloid angiopathy or
other significant cerebrovascular disease.
To assess the possible influence of Aβ-induced phosphor-
ylation of α-syn on cognitive decline in PD patients, ourarkinson’s disease dementia (PDD) and dementia with
PDND (n = 23) PDD (n = 12) DLB (n = 10)
61.1 ± 9.1 58.2 ± 7.7 69.7 ± 7.3
77.7 ± 6.2 77.85 ± 6.1 77.0 ± 9.0
16.6 ± 6.7 19.7 ± 6.5 7.3 ± 2.0
13 (57) female 6 (50) female 4 (40) female
63.6 ± 27.0 38.2 ± 21.7 28.0 ± 10.9
N/A 14.6 ± 6.9 N/A
II (I to IV) II (I to IV) II (0 to III)
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PDD, and the score on the MMSE within the last year
of life, where available.
In all cases consent had been given for the use of brain
tissue and for access to the patients’ clinical records for
research.
Tissue preparation
Brain tissue (200 mg) samples of midfrontal, cingulate
and parahippocampal cortex and thalamus were sequen-
tially extracted in 1% NP-40 buffer (140 mM NaCl,
3 mM KCl, 25 mM TRIS, 5 mM ethylenediaminetetraace-
tic acid (EDTA), 2 mM 1,10 phenanthroline) as previously
described for Aβ measurements in human post-mortem
tissue [46,48,49,52]. The tissue was homogenized in a Pre-
cellys 24 homogenizer (Stretton Scientific, Derbyshire,
UK) with 2.3 mm ceramic beads (Biospec, Stratech,
Suffolk, UK). The homogenates were spun at 13,000 × g
for 15 minutes at 4°C and the supernatant was removed
and stored at −80°C. Insoluble material was solubilized by
vigorous agitation in 6 M GuHCl, re-homogenized and
left for four hours at room temperature (RT) before
storage at −80°C.
Total α-syn sandwich ELISA
Total α-syn level was determined by sandwich ELISA.
Mouse monoclonal anti-α-syn antibody (0.5 μg/ml; BD
Biosciences, Oxford, UK) was coated onto a NUNC
Maxisorp 96-well plate overnight at RT. The plate was
washed in PBS/0.01% tween-20 and blocked for 1.5 hours
in 1% BSA/PBS. Tissue samples (insoluble and soluble ex-
tracts diluted 1:200 in PBS) were added for two hours at
RT with constant shaking. The plate was rinsed, tapped
dry and biotinylated polyclonal anti-α-synuclein (1 μg/ml;
R&D Systems, Oxford, UK) diluted in PBS was added for
two hours at RT. The plate was rinsed and tapped dry,
streptavidin-horseradish peroxidase (HRP) (1:200, R&D
Systems) was added for 20 minutes and, after further
washing, chromogenic substrate (TMBS, R&D Systems)
was added for 20 minutes in the dark. The reaction was
stopped with 2 N sulfuric acid and absorbance at 450 nM
read in a FLUOstar Optima plate reader (BMG Labtech,
Aylesbury, UK). Total α-syn levels were interpolated from
measurements made on serial dilutions of recombinant
human α-syn ranging from 62.5 to 0.98 ng/ml (rPeptide,
Stratech, Suffolk, UK). Measurements for each sample
were repeated in duplicate.
pSer129 α-syn sandwich ELISA
Mouse monoclonal anti-α-syn antibody (0.5 μg/ml; BD
Biosciences) was coated onto a NUNC Maxisorp 96-well
plate overnight at RT. The plate was washed in PBS/
0.01% tween-20 and blocked for two hours in 1% BSA/
PBS. Tissue samples (insoluble extracts diluted 1:99 inPBS, soluble extracts diluted 1:3) were added for five
hours at RT with constant shaking. The plate was rinsed
and tapped dry and anti-pSer129 α-syn (0.8 μg/ml; Abcam,
Cambridge, UK) diluted in PBS was added and left to incu-
bate at 4°C overnight. Following washing of the plate,
biotinylated horse anti-rabbit antibody (1.5 μg/ml; Vector
labs, Peterborough, UK) diluted in PBS with 0.01% tween-20
was added for one hour at RT. The plate was rinsed and
tapped dry, streptavidin-HRP was added for one hour
followed by chromogenic substrate for 20 minutes in the
dark. The reaction was stopped with 2 N sulfuric acid
and absorbance at 450 nM read in a FLUOstar Optima
plate reader (BMG Labtech). The concentration of pSer129
α-syn was determined as described previously [53], by
interpolation from measurements of serial dilutions (200
to 3.125 ng/ml) of recombinant α-syn that had been phos-
phorylated at Ser129 by incubating with casein kinase II
(see below).
Specificity of the pSer129 α-syn antibody
We conducted a preliminary study to confirm the speci-
ficity of the pSer129 α-syn antibody. Full-length recom-
binant human α-syn (1 mg/ml; rPeptide, Statech) was
incubated with casein kinase I (CKI) (1,000 units, New
England Biolabs, Hitchin, UK) or casein kinase II (CKII)
(500 units, New England Biolabs, one unit being defined
as the amount of CKII required to catalyze the transfer
of 1 ρmol of phosphate to 100 μM CKII peptide se-
quence RRRADSDDDDD in one minute at 30°C) for
one hour at 30°C in the presence of 200 μM ATP (New
England Biolabs) (protocol adapted from Lee et al. [54];
Walker et al. [45]). As a control, another sample was
treated in the same manner in the absence of either CKI
or CKII. Samples were diluted in 1% Tris-buffered saline
(TBS) (1:400) and applied to a pre-wetted (in 1% TBS) nitro-
cellulose membrane and incubated at room temperature for
one hour. The membrane was washed in 0.3% Tris-buffered
saline with Tween 20 (TBST) then incubated with 10% non-
fat milk in 0.3% TBST for one hour at RT with agitation to
prevent non-specific binding. After washing the membrane
in TBST, primary antibodies (total α-syn, 0.5 μg/ml,
BD Biosciences; pSer129 α-syn, 0.8 μg/ml, Abcam; pSer87
α-syn, 200 μg/ml, Santa Cruz, Dallas, TX, USA) diluted in
5% non-fat milk in TBST were applied overnight. The fol-
lowing day the membrane was again washed in TBST and
incubated with peroxidase-conjugated secondary antibody
diluted in 5% non-fat milk in TBST for one hour at
RT with agitation. The membrane was washed and
then developed on photographic film using Immobi-
lon™chemiluminescence reagents (Millipore, Danvers,
MA, USA) according to the manufacturer’s guidelines.
The pSer129 α-syn antibody labelled α-syn following in-
cubation with CKII, and to a lesser extent CKI, but did not
label recombinant α-syn that had not been phosphorylated
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specific α-syn antibody (BD Biosciences) detected all forms
of α-syn, and a pSer87-specific α-syn antibody detected a
signal only after incubation of α-syn with CKI (as expected
from previous studies by Okochi et al. [55] and Paleologou
et al. [40]). These findings confirmed the specificity of the
pSer129 α-syn antibody (see Additional file 1: Figure S1).
Aβ40 sandwich ELISA
The level of Aβ40 was measured in post-mortem brain
tissue samples by sandwich ELISA as described [49,56].
High-binding Costar 96-well plates (R&D Systems) were
coated with anti-human Aβ (2 μg/ml; clone 6E10, raised
against amino acids 4–7, Covance, Maidenhead, UK) di-
luted in PBS and incubated overnight at RT. After five
washes with PBS containing 0.05% tween-20, the plates
were blocked with 300 μL protein-free PBS blocking buffer
(Thermo Fisher Scientific, Loughborough, UK) for two
hours at RT. After a further five washes, brain homogenate
samples (insoluble extracts diluted 1:49, soluble extracts
diluted 1:3) and serial dilutions of recombinant human
Aβ1-40 (Sigma Aldrich, Dorset, UK) in PBS containing
1% 1,10 phenanthroline (Sigma Aldrich) (to prevent
degradation of Aβ [57]) were incubated for two hours
at RT with rocking. After a further wash step, the plates
were incubated with anti-human Aβ1-40 (1 μg/ml;
Covance) for two hours at RT. The antibody was pre-
pared using the Lightning-Link biotinylation kit (Innova
Biosciences, Cambridge, UK) according to the manu-
facturer’s guidelines. After further washes, the plate
was rinsed and tapped dry, streptavidin-HRP added for
20 minutes, and chromogenic substrate for 20 minutes
in the dark. The reaction was stopped with 2 N sulfuric
acid and absorbance at 450 nM read in a FLUOstar
Optima plate reader (BMG Labtech). The Aβ1–40 level in
the brain tissue samples was interpolated from a standard
curve generated by serial dilution of recombinant human
Aβ1–40 (Sigma Aldrich) in the range 16,000 to 1.024 nM.
Each sample was assayed in duplicate.
Aβ42 sandwich ELISA
The level of Aβ42 was measured in post-mortem brain
tissue samples by sandwich ELISA as outlined above
with a few modifications. Anti-human Aβ1-42 (0.5 μg/ml;
12 F4, Covance) was used as the capture antibody. Tissue
samples (insoluble extracts diluted 1:9, soluble extracts
diluted 1:3) were incubated at RT for four hours. Biotinyl-
ated anti-human Aβ (0.1 μg/ml; Thermo Fisher Scientific)
diluted in PBS was used for detection and incubated over-
night at 4°C. Following washing, rinsing and drying,
streptavidin-HRP was added to the plate for one hour and
chromogenic substrate for 20 minutes in the dark. Aβ1-42
concentration in brain tissue was interpolated from a
standard curve generated by serial dilution (16,000 to1.024 nM) of recombinant human Aβ1–42 (Sigma Aldrich).
Each sample was assayed in duplicate. The Aβ1-42 ELISA
did not detect Aβ1-40, and the Aβ1-40 ELISA did not
detect Aβ1-42.
Sandwich ELISA validation
Intra-assay and inter-assay coefficients of variation were
calculated for the ELISAs as well as spike and recovery
tests (see Additional file 2: Table S3), in which serial di-
lutions of Aβ40, Aβ42, α-syn or pSer129 α-syn were
added to brain homogenates rather than assay diluent.
The recovered:added ratio for each added protein (a ratio
sometimes termed the response rate) and the correlation
between the calculated concentration and measured con-
centration of added protein were assessed in the insoluble
and soluble fractions of the homogenates. The recovered:
added ratios of soluble and insoluble pSer129 α-syn (the
former well below 1, the latter well above 1) suggests that
on addition to brain homogenates, which already con-
tained relatively high baseline amounts of α-syn as well as
some pSer129 α-syn, most of the added soluble pSer129
α-syn rapidly aggregated and entered the insoluble frac-
tion in the homogenate. Data from the total α-syn and
Aβ42 assays indicated a good recovery rate, with recovery
of Aβ40 being 50%. In all of the assays there was a very
close linear correlation between the concentration of
added protein and the concentration of protein determined
by the assay (as shown by the Pearson r and P values),
enabling valid comparisons to be made between brains
and also between cohorts.
Immunohistochemical assessment of α-syn, pSer129 α-syn,
Aβ42 and Aβ40
Formalin-fixed paraffin-embedded sections of mid-frontal,
cingulate, parahippocampal cortex and thalamus in all
DLB cases were immunolabelled for Aβ1-42 (0.5 μg/ml;
Covance), Aβ1-40 (1 μg/ml; Covance), pSer129 α-syn
(0.8 μg/ml; Abcam) and α-syn (80 mg/l; Vector Labs,
Peterborough, UK) by use of a standard streptavidin-
biotin-HRP immunohistochemistry protocol [58]. The
extent of immunolabelling of each antigen was mea-
sured by field fraction analysis with the help of Image
Pro Plus™ software (Media Cybernetics, Marlow, UK)
driving a Leica DM microscope with a motorized stage.
The software made an unbiased selection of twelve ×
20-objective fields and the percentage area immunopo-
sitive for the relevant antigen was determined for each
section, as outlined previously [59,60].
Cell culture
SH-SY5Y neuroblastoma cells were transfected with a
pCDNA3.1 vector (Life Technologies, UK) containing
wild-type human SNCA cDNA under the control of a
cytomegalovirus (CMV) promoter. Transfection was carried
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by selection of clones (and their subsequent maintenance)
in culture medium containing 0.3 mg/ml G418 (Geneticin,
Life Technologies, Paisley, UK). The culture medium for
SH-SY5Y cells, either untransfected or stably expressing hu-
man wild-type α-syn, consisted of 42% vol/vol Ham’s F12
nutrient mixture (F12) (Sigma) and 42% vol/vol Eagle’s
minimum essential medium (Sigma), supplemented
with 15% vol/vol fetal calf serum (Sigma), 2 mM L-glutamine
(Sigma), 1% vol/vol non-essential amino acids solution
(Sigma), 20 units/mL penicillin, 20 mg/mL streptomycin
(Sigma) and 250 ng/mL amphotericin B (Life Technologies)
at 37°C in 5% CO2 (21% O2).
Addition of Aβ to cell cultures
Before treatment with Aβ, the culture medium was re-
placed with serum-free medium (no fetal bovine serum
and no G418) for 24 hous. Aβ solutions were also preparedFigure 1 Correlation between Aβ and insoluble pSer129 α-syn. Each p
lines) and 95% confidence intervals (interrupted lines) are superimposed. O
shown in the figure. Significant positive correlations between insoluble pSe
(PH) cortex and thalamus (TH). Significant positive correlations were also foun
(CG) and PH cortex. In addition, significant correlations were found between
CG cortex. Aβ, amyloid-β; pSer129 α-syn, alpha-synuclein phosphorylate24 hours in advance. Stock solutions of 1 mM Aβ42 and
Aβ40 (Cambridge Biosciences, Cambridge, UK) in 35%
acetonitrile were diluted in serum-free medium at 1 μM
and 10 μM. The Aβ was either left overnight to aggregate
at 26°C for 24 hours (as previously described [61]) or im-
mediately placed overnight in a −80°C freezer. Aβ (either
aggregated or fresh) was added to flasks the following day
(10 μM acetonitrile was added to control flasks) and incu-
bated for 24 hours.
Preparation of cell lysates for sandwich ELISA
Cells were incubated with Dulbecco’s PBS without cal-
cium chloride and magnesium chloride (Sigma-Aldrich)
at 37°C for five minutes and then removed from the
flask, transferred into a Falcon tube, and spun for three
minutes at 13,000 rpm. The cells were washed in PBS
and lysed in 100 μl non-denaturing proprietary cell lysis
buffer (Sigma-Aldrich, Dorset, UK) according to theoint represents a separate case. The best-fit linear regression (solid
nly significant P-values (and associated correlation coefficients) are
r129 α-syn and soluble Aβ42/Aβ40 were found in the parahippocampal
d between insoluble pSer129 α-syn and insoluble Aβ42 in the cingulate
insoluble pSer129 α-syn and insoluble Aβ40 in the midfrontal and
d at serine 129.
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15 minutes at 4°C. Cell supernatants (soluble fraction)
were removed and stored at −80°C until used. A total
of 6 M GuHCl (100 μl) was added to the remaining in-
soluble pellet and left at RT for 1.5 hours (insoluble
fraction) before the tube was stored at −80°C.
Statistical analysis
Whenever possible, parametric statistical tests were used for
comparisons between groups (in some cases this required
logarithmic transformation of the data to obtain a normal
distribution): analysis of variance (ANOVA) with Dunnett’s
test for pairwise intergroup comparisons, or repeated mea-
sures ANOVA for the analysis of in vitro measurements on
cells exposed to different concentrations of Aβ during the
same experiment. For variables that were not normallyFigure 2 Correlation between Aβ and soluble pSer129 α-syn. Each po
and 95% confidence intervals (interrupted lines) are superimposed. Only sig
the figure. Significant negative correlations between soluble Aβ42 and solu
(TH). In contrast, a significant positive correlation was found between soluble
negative correlations were found between soluble Aβ40 and soluble pSer129
negative correlations were also found between soluble pSer129 α-syn an
correlation was observed between soluble pSer129 α-syn and insoluble
phosphorylated at serine 129.distributed even after transformation, the Kruskall-Wallis
test was used, with Dunn’s test for pairwise intergroup com-
parisons. Pearson or Spearman analysis was used as appro-
priate to assess the correlation between pairs of variables.
Statistical tests were performed using GraphPad Prism v5.
P-values <0.05 were considered statistically significant.
Results
pSer129 α-syn correlates with insoluble and soluble Aβ
In most regions the level of insoluble pSer129 α-syn in-
creased as the levels of Aβ40 and Aβ42 increased (Figure 1,
Additional file 3: Table S1), with significant positive corre-
lations between insoluble pSer129 α-syn and soluble Aβ40
and Aβ42 in the parahippocampal cortex (soluble Aβ40:
r = 0.376, P = 0.003; soluble Aβ42: r = 0.287, P = 0.024)
and thalamus (soluble Aβ40: r = 0.398, P = 0.002; solubleint represents a separate case. The best-fit linear regression (solid lines)
nificant P-values (and associated correlation coefficients) are shown in
ble pSer129 α-syn were found in the cingulate (CG) cortex and thalamus
Aβ42 and soluble pSer129 α-syn in the midfrontal (MF) cortex. Significant
α-syn in the CG, parahippocampal (PH) cortex and TH. Significant
d insoluble Aβ42 in the MF cortex and TH. A significant positive
Aβ40 in the PH cortex. Aβ, amyloid-β; pSer129 α-syn, alpha-synuclein
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tions were also found between insoluble pSer129 α-syn
and insoluble Aβ42 in the cingulate (r = 0.293, P = 0.022)
and parahippocampal cortex (r = 0.314, P = 0.013) as well
as between insoluble pSer129 α-syn and insoluble Aβ40 in
the midfrontal (r = 0.719, P <0.0001) and cingulate cortex
(r = 0.304, P = 0.017). Significant negative correlations
between soluble pSer129 α-syn and soluble Aβ42 were
found in the cingulate cortex and thalamus (Figure 2;
Additional file 3: Table S1) (cingulate cortex: r = −0.287,
P = 0.035; thalamus: r = −0.373, P = 0.0036). In contrast, a
significant positive correlation was observed between sol-
uble Aβ42 and soluble pSer129 α-syn in the midfrontal
cortex (r = 0.443, P = 0.0015). Significant negative correla-
tions between soluble Aβ40 and soluble pSer129 α-syn
were found in three of four regions (cingulate cortex:
r = −0.313, P = 0.021; parahippocampal cortex: r = −0.286,
P = 0.028; and thalamus: r = −0.376, P = 0.0033). Sig-
nificant negative correlations were also found between
soluble pSer129 α-syn and insoluble Aβ42 in the mid-
frontal cortex and thalamus (midfrontal cortex: r = −0.475,
P = 0.0005; thalamus: r = −0.399, P = 0.0018). A significant
positive correlation between soluble pSer129 α-syn and
insoluble Aβ40 was also found in the parahippocampus
(r = 0.316, P = 0.015).
Field fraction analysis of the extent of immunohisto-
chemical labeling of these antigens in the DLB cases re-
vealed a significant positive correlation between pSer129Figure 3 Correlation between pSer129 α-syn and Braak stage in comb
a separate case. The best-fit linear regression (solid lines) and 95% confidence
(and associated correlation coefficients) are shown in the figure. Insoluble pSe
cortex. Soluble pSer129 α-syn level correlated negatively with Braak stage in t
disease; pSer129 α-syn, alpha-synuclein phosphorylated at serine 129.α-syn and Aβ42 in the mid-frontal region only (r = 0.849,
P = 0.0019) (see Additional file 4: Table S2). There was
only weak, non-significant correlation between the level of
these antigens in the brain homogenates and the percent-
age area labeled in paraffin sections from the correspon-
ding regions in the contralateral cerebral hemisphere.
Insoluble pSer129 α-syn level correlates with Braak tangle
stage
The insoluble pSer129 α-syn level correlated positively
with the Braak tangle stage only in the mid-frontal cor-
tex (Figure 3) (r = 0.526, P = 0.0002). Soluble pSer129 α-
syn levels correlated negatively with the Braak stage in
the cingulate region only (r = −0.335, P = 0.028).
Insoluble Aβ is higher in disease groups than controls
and in DLB than PD in most regions
The level of insoluble Aβ42 in the cingulate and para-
hippocampal cortex was significantly higher in all dis-
ease cohorts than controls (Figure 4). The DLB cohort
had a significantly higher level of insoluble Aβ42 in the
midfrontal cortex than did any of the other groups. In
contrast, the level of insoluble Aβ42 in the thalamus was
higher in the PD cohorts than in DLB or controls.
Similar results were observed for insoluble Aβ40, with
some regional differences. In the midfrontal and cingu-
late cortex it was present at a significantly higher level in
all disease groups than controls. The level of insolubleined PD (n = 35) and DLB (n = 10) patients. Each point represents
intervals (interrupted lines) are superimposed. Only significant P-values
r129 α-syn level correlated positively with Braak stage in the midfrontal
he cingulate cortex. DLB, dementia wth Lewy bodes; PD, Parkinson’s
Figure 4 Insoluble Aβ and α-syn levels in controls, PDND, PDD and DLB. Box-and-whisker plots indicate the full range, interquartile range
and median value in each group. Insoluble Aβ42 level was significantly higher in DLB than controls in all regions except the thalamus. It was also
significantly higher in DLB than PDND or PDD in the midfrontal region but lower in the thalamus. In all regions except the midfrontal, the insoluble
Aβ42 level was significantly higher in both PDND and PDD than controls. The insoluble Aβ40 level was significantly greater in midfrontal and cingulate
cortex and thalamus in PDND, PDD and DLB than controls, and in the parahippocampus the level was significantly higher in DLB than in PDND or
PDD but not controls. The total insoluble α-syn level was significantly higher in PDD than controls or PDND in midfrontal cortex and higher than in
DLB or controls in the parahippocampus. Total insoluble α-syn in the cingulate cortex was significantly higher in DLB than in PDND or controls.
No significant differences between groups were observed in the thalamus. Aβ, amyloid-β; DLB, dementia with Lewy bodies; PDD, Parkinson’s
disease with dementia; PDND, Parkinson’s disease without dementia; α-syn, α-synuclein.
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DLB than controls.
Soluble Aβ is higher in disease groups than controls and
in dementia groups than PDND in several regions
The level of soluble Aβ42 was significantly higher in the
PD cohorts than controls in all regions (Figure 5). The
level in the parahippocampal cortex was significantly
higher in DLB than PDND or controls, and in the mid-
frontal and cingulate cortex it was higher in PDD than
DLB. All disease groups had a significantly higher level
of soluble Aβ40 than controls in most regions.
Total insoluble α-syn varies modestly between disease
groups
The level of insoluble α-syn in the midfrontal and parahip-
pocampal cortex (Figure 4) was significantly higher in PDD
than in PDND or controls whereas in the DLB cohort the
level was significantly higher in the cingulate region only.
No significant differences were found between groups in
the thalamus. No significant differences between controls
and PDND were found in any region.Total soluble α-syn is higher in PD than controls but
lower in DLB than PD
The level of soluble α-syn (Figure 5) was significantly
higher in PDND than controls in all regions, and in
PDD than controls in the midfrontal and parahippocam-
pal cortex and thalamus. Unexpectedly, the DLB cohort
had significantly lower soluble total α-syn than the PD
groups in most regions.
Insoluble pSer129 α-syn is higher and soluble pSer129
α-syn is lower in disease groups than controls
In most regions, the proportion of insoluble α-syn that
was phosphorylated at Ser129 was significantly higher in
the PDD and DLB groups than the controls (Figure 6)
and in several regions the proportion was significantly
higher in both PDD and DLB than PDND. Conversely,
in the soluble fraction, the proportion of α-syn that was
phosphorylated at Ser129 was significantly higher in
controls than disease groups in most regions (Figure 7).
Irrespective of cohort, a significantly higher proportion
of α-syn was phosphorylated at Ser129 in the insoluble
than the soluble fractions (data not shown; P <0.001).
Figure 5 Soluble Aβ and α-syn levels in controls, PDND, PDD and DLB. Box-and-whisker plots indicate the full range, interquartile range and
median value in each group. Soluble Aβ42 level was significantly higher in PDND and PDD than controls in all regions, and in the midfrontal and
cingulate cortex, it was significantly higher in PDD than DLB. In DLB the level of soluble Aβ42 was significantly higher than in controls and PDND
in the parahippocampus and higher than controls in the thalamus. The soluble Aβ40 level was significantly elevated in PDND and PDD compared
with controls in all regions. The level was also significantly higher in DLB than in controls in all regions except the cingulate cortex. Soluble total
α-syn levels were significantly greater in PDND than controls in all regions, and significantly higher in PDD than controls in the midfrontal cortex,
parahippocampus and thalamus. *P <0.05, **P <0.01, ***P <0.001. Aβ, amyloid-β; DLB, dementia with Lewy bodies; PDD, Parkinson’s disease with
dementia; PDND, Parkinson’s disease without dementia; α-syn, α-synuclein.
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Additional file 5: Figure S2.
MMSE score correlates negatively with insoluble pSer129
α-syn, total insoluble α-syn and insoluble Aβ42
In all regions apart from the thalamus, the MMSE score
correlated negatively with the level of insoluble pSer129
α-syn (Figure 8) (midfrontal: r = −0.555, P = 0.017; cin-
gulate: r = −0.816, P <0.0001; parahippocampal cortex:
r = −0.752, P = 0.0003). Furthermore, in the midfrontal
region there was a significant negative correlation between
the MMSE score and both insoluble Aβ42 (r = −0.591,
P = 0.0098) and total insoluble α-syn (r =−0.498, P = 0.036).
No significant correlations were observed between MMSE
score and soluble Aβ42, Aβ40, total α-syn or pSer129
α-syn. Time to dementia correlated negatively with sol-
uble Aβ40 in this region (r = −0.58, P = 0.048) but did not
show any other significant correlations (data not shown).
Aβ treatment induced phosphorylation at Ser129 in
α-syn-overexpressing SHSY-5Y cells
Exposure of cells to aggregated Aβ1-42 (10 μM) sig-
nificantly increased the percentage of α-syn in theinsoluble fraction that was phosphorylated at Ser129.
Ser129 phosphorylation was also higher after exposure to
soluble 10 μM Aβ1-42 and aggregated (but not fresh)
10 μM Aβ1-40 but these increases did not reach statis-
tical significance (Figure 9). There was a trend towards
a positive correlation (Spearman r = 0.49, P = 0.06)
between the concentration of aggregated Aβ and the
percentage of α-syn phosphorylated at Ser129. In the
soluble fraction, the percentage of α-syn that was
phosphorylated at Ser129 was much lower and tended
to decline after exposure to aggregated Aβ1-42 and
Aβ1-40 but not after exposure to fresh Aβ (Figure 10).
Discussion
Although overlap between AD and DLB pathology occurs
much more often than would be expected by chance, the
molecular basis is poorly understood. Furthermore, the
molecular changes underlying the development of demen-
tia in patients with PD are not fully understood. We found
that most parts of the cerebral cortex examined showed:
(1) significant correlations between phosphorylation of
α-syn at Ser129 and the amount of soluble and insoluble
Aβ; (2) significant correlations between phosphorylation
Figure 6 Percentage of insoluble α-syn phosphorylated at Ser129. Box-and-whisker plots indicate the full range, interquartile range and
median value in each group. The percentage of insoluble α-syn phosphorylated at Ser129 was significantly higher in PDD than controls in
all regions and in DLB in regions except the midfrontal cortex. In addition, the percentage was significantly higher in PDD than PDND in the
midfrontal and parahippocampal cortex, and in DLB than PDND in the cingulate cortex. In the thalamus and parahippocampal cortex, the
percentage of insoluble α-syn phosphorylated at Ser129 was significantly higher in PDND than controls. DLB, dementia with Lewy bodies;
PDD, Parkinson’s disease with dementia; PDND, Parkinson’s disease without dementia; α-syn, α-synuclein.
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uble and insoluble Aβ in PD and DLB than controls, and
PDD and DLB than PDND; and (4) a higher proportion of
α-syn phosphorylated at Ser129 in PD and DLB than con-
trols, and PDD and DLB than PDND. Our study also
showed that the proportion of α-syn phosphorylated at
Ser129 correlated with ante-mortem MMSE. Lastly, our
in vitro studies showed that exposure of SH-SY5Y cells
overexpressing wild-type α-syn to Aβ42 significantly
increased the proportion of α-syn that was phosphory-
lated at Ser129. These biochemical studies extend pre-
vious findings of a synergistic relationship between Aβ
and α-syn and suggest that Aβ, particularly Aβ42, pro-
motes the phosphorylation of α-syn at Ser129.
Our biochemical studies support previous immunohis-
tochemical findings of a positive correlation between in-
soluble α-syn and Aβ in Lewy body disease [25,26,62-64].In addition, our finding of a correlation with Braak stage,
although more restricted in terms of regions of the cortex,
is in keeping with other studies showing associations
between α-syn and tangle pathology [7,44] and suggest
that there are multiple interactions between Alzheimer-
type and Lewy body-type pathology. Deramecourt et al.
[7] reported that all patients with sporadic DLB had
abundant deposits of Aβ42. In addition, in families
with autosomal-dominant AD caused by amyloid pre-
cursor protein (APP) or presenilin gene mutations, a
high proportion of patients show LB pathology at aut-
opsy [65,66]. Furthermore, patients with mixed LB and
Aβ plaque pathology have a more aggressive disease
course and more pronounced cognitive dysfunction
than do patients with pure AD [19,21-23]. Transgenic
mice expressing both human Aβ and α-syn also have
more severe deficits in learning and memory, and more
Figure 7 Percentage of soluble α-syn phosphorylated at Ser129. The percentage of soluble α-syn phosphorylated at Ser129 was significantly
higher in controls than in the PD groups in all regions except midfrontal. The percentage of soluble α-syn phosphorylated at Ser129 was also
significantly higher in controls than DLB in the cingulate. Conversely, the percentage was significantly higher in DLB than PDND or PDD in
the parahippocampus and thalamus and significantly higher in PDND than DLB in the midfrontal cortex. *P <0.05, **P <0.01, ***P <0.001.
DLB, dementia with Lewy bodies; PDD, Parkinson’s disease with dementia; PDND, Parkinson’s disease without dementia; α-syn, α-synuclein.
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for α-syn alone [28]. Other evidence comes from the
observation by Kurata et al. [67], of enhanced accumu-
lation of both Aβ and phosphorylated α-syn in mice
doubly transgenic for mutant APP and presenilin-1 com-
pared to that in mice transgenic for APP alone.
Obi et al. [44] demonstrated an association between
Aβ and pSer129 α-syn detected immunohistochemically
in the human temporal neocortex human tissue, and we
found a similar correlation in the mid-frontal cortex.
However, it was noteworthy that the correlation between
Aβ and pSer129 α-syn was less consistent in different
brain regions when we quantified these antigens immu-
nohistochemically than by ELISA, and only a weak, non-
significant correlation was demonstrated between the
immunohistochemical and biochemical measurements.
Several previous studies have highlighted disparitiesbetween ELISA and immunohistochemistry [68-70].
Some of these disparities are thought to reflect the ef-
fects of formalin fixation and tissue processing on the
preservation of antigenic epitopes, and others may relate
to a degree of cross-linking of soluble and insoluble pro-
teins, preventing their separate analysis in the fixed,
paraffin-embedded tissue. In addition, sandwich ELISAs
provide an objective measure of the actual concentration
of the analyte in a much larger, more representative vol-
ume of tissue than is included in a paraffin section, and
relies on a combination of two different antibodies for
specificity. Our biochemical methods also allowed us to
measure soluble protein. The significant negative corre-
lations between soluble pSer129 α-syn and Aβ are in
keeping with an enhanced shift of pSer129 α-syn into
the insoluble fraction as a consequence of Aβ. The
present findings highlight the importance of combining
Figure 8 Correlation between MMSE score and insoluble Aβ or α-syn. The best-fit linear regression (solid lines) and 95% confidence intervals
(interrupted lines) are superimposed. Only significant P-values (and associated correlation coefficients) are shown in the figure. In all regions except
the thalamus, the level of insoluble pSer129 α-syn showed significant negative correlation with the MMSE score. The score also showed a significant
negative correlation with midfrontal insoluble Aβ42 and total insoluble α-syn. Aβ, amyloid-β; MMSE, mini-mental state examination; pSer129 α-syn,
alpha-synuclein phosphorylated at serine 129; α-syn, α-synuclein.
Swirski et al. Alzheimer's Research & Therapy 2014, 6:77 Page 12 of 17
http://alzres.com/content/6/9/77biochemical assessment with immunohistochemical me-
thods when studying the quantitative relationship bet-
ween different proteins.
Direct molecular interaction between α-syn and Aβ was
demonstrated in vitro, by multidimensional nuclear mag-
netic resonance (NMR) spectroscopy [71]. Aβ42 interacted
more strongly than Aβ40 with α-syn, leading to major
structural changes to α-syn, and its oligomerization and
precipitation within four hours. These findings may be
relevant to the observation by Bate et al. [72] who ob-
served that Aβ42 (but not Aβ40) enhanced α-syn-induced
damage to synapses. Aβ42 more strongly promoted the
formation of higher molecular weight α-syn polymers
in vitro [28]. In keeping with this, we found that Aβ42
level generally correlated more strongly with pSer129α-syn in human brain tissue extracts than with Aβ40.
We also showed that Aβ42 had a more pronounced
effect than Aβ40 on the phosphorylation of α-syn in
SH-SY5Y cells.
In vitro studies have shown that α-syn can be phos-
phorylated at Ser129 by CKI, CKII [55], several G protein-
coupled receptor kinases (GRKs 1, 2, 5, 6) [73], leucine-rich
repeat kinase 2 (LRRK2) [74] and Polo-like kinases [75,76].
The levels of CKI and CKII expression are elevated in both
AD and DLB [76,77], raising the possibility that these
enzymes may be involved in Aβ-induced phosphoryl-
ation of α-syn at Ser129, similar to the Aβ-induced
phosphorylation of tau [78-80].
More than 90% of α-syn in Lewy bodies and neurites
is phosphorylated at Ser129 [34,35]. The importance of
Figure 9 Percentage of insoluble α-syn phosphorylated at Ser129 after exposure of SH-SY5Y cells to aggregated or soluble Aβ1-42
and Aβ1-40. The percentage of insoluble α-syn that was phosphorylated at Ser129 was significantly increased after 24 hours exposure of the cells
to 10 μM aggregated Aβ1-42 (P = 0.009). Ser129 phosphorylation was also higher after exposure to soluble 10 μM Aβ1-42 and aggregated 10 μM
Aβ1-40 but the increases did not reach significance. Aβ, amyloid-β.
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Synucleinopathy Staging Scheme of Beach et al. [43],
based on the abundance and distribution of pSer129 α-
syn. We have shown that biochemical measurement of
pSer129 α-syn by sandwich ELISA is an excellent marker
of Lewy body disease subtype. Previous studies have
demonstrated the utility of pSer129 α-syn measure-
ment as a marker of disease stage [43,44] and shown
that the level is generally higher in DLB and PDD than in
PDND [45]. The accumulation of pSer129 anticipates the
development of Lewy body pathology [45,81]. The parti-
tioning and enrichment of pSer129 α-syn in membrane
and insoluble brain fractions probably reflects changes in
the conformation and solubility of α-syn that promote its
association with membrane structures [82-84]. Our data
show that exposure of SH-SY5Y cells overexpressing wild-
type α-syn to Aβ results in a shift towards insoluble
pSer129 α-syn, with a trend towards loss of soluble
pSer129 α-syn. In future studies it would be of interest toinvestigate the distribution of α-syn and pSer129 α-syn fol-
lowing Aβ exposure in this cell model and to determine
the enzymes responsible.
We have found a significant negative correlation between
the level of insoluble pSer129 α-syn and the MMSE score.
This supports previous work suggesting that Ser129 phos-
phorylation increases the neurotoxicity of α-syn and is det-
rimental to cognitive function. Sato et al. [85] showed that
pSer129 α-syn accelerated A53T α-syn-induced neurode-
generation; this effect was abolished by inactivation of
G-protein-coupled receptor kinase 6 (GRK6) – respon-
sible for phosphorylation of α-syn at Ser129. In con-
trast, enhancement of phosphatase activity in α-syn
transgenic mice caused a reduction of phosphorylated
α-syn, increased dendritic arborization of neurons in
the cerebral cortex and reduced astroglial and micro-
glial activation [39]. These morphological effects were
associated with improved motor performance. Phos-
phorylation of α-syn at Ser129 was also shown to reduce
Figure 10 Percentage of soluble α-syn phosphorylated at Ser129 after exposure of SH-SY5Y cells to aggregated or soluble Aβ1-42 and
Aβ1-40. The percentage of soluble α-syn phosphorylated at Ser129 was much lower than the figure for insoluble α-syn. The percentage tended
to fall after exposure to aggregated Aβ1-42 and Aβ1-40, particularly at 10 μM, but not significantly so, and did not change noticeably after
exposure to soluble Aβ. The bars show the mean and SE of measurements from five separate experiments. Aβ, amyloid-β.
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zyme involved in catecholamine synthesis; therefore,
phosphorylation of α-syn may influence dopamine levels
[86]. Although Aβ42, Aβ40 and total α-syn levels in sev-
eral brain regions all correlated negatively with MMSE
score, those correlations were not as strong as that be-
tween MMSE score and pSer129 α-syn. Our findings
underscore the close association between pSer129 α-syn
accumulation and cognitive impairment, and do point to a
pathogenetic relationship between Ser129 phosphorylation
of α-syn and disease progression.
Conclusions
Our findings in this study, the first to examine the rela-
tionship between α-syn, pSer129, Aβ1-40 and Aβ1-42
levels in human post-mortem brain tissue by sandwich
ELISA, support the existence of a pathogenic relationship
between the accumulation of Aβ, particularly Aβ42, and
the phosphorylation of α-syn at Ser129, increasing the se-
verity of Lewy body disease and the likelihood of demen-
tia. Further investigations are required to determine theprecise biochemical pathways responsible for this inter-
action, the relative contributions of different processes (in-
cluding Aβ-associated Ser129 phosphorylation of α-syn
and α-syn-associated phosphorylation of tau) on the de-
velopment of combined AD and Lewy body pathology and
the progression of neurodegeneration, and also the pos-
sible influence of Aβ on other potential sites of α-syn
phosphorylation.Additional files
Additional file 1: Figure S1. Dot blots demonstrating the specificity of
the phosphorylation-specific α-syn antibodies. Blots of recombinant α-syn
incubated with distilled water (α-syn) casein kinase I (α-syn + CKI) or casein
kinase II (α-syn + CKII) and probed with pan-α-syn (column 1), pSer129 α-syn
(column 2) or pSer87 α-syn (column 3) antibody. The pSer129 α-syn
antibody labelled α-syn following incubation with CKII, and to a lesser
extent CKI, but did not label recombinant α-syn that had not been
phosphorylated with CKI or CKII. Labeling with the pSer87-specific α-syn
antibody occurs only after incubation of α-syn with CKI. These findings are
as predicted from the known patterns of phosphorylation of α-syn with CKI
and CKII.
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http://alzres.com/content/6/9/77Additional file 2: Table S3. Intra-assay coefficient of variation (CV) from
insoluble (shaded) and soluble Aβ42, Aβ40, total α-syn and pSer129 α-syn
ELISAs.
Additional file 3: Table S1. Correlation between levels of Aβ and α-syn
in the midfrontal, cingulate and parahippocampal cortex and the thalamus.
Additional file 4: Table S2. Correlation between levels of Aβ and α-syn
in the midfrontal, cingulate and parahippocampal cortex and the thalamus
from immunohistochemistry field fraction analyses.
Additional file 5: Figure S2. pSer129 α-syn levels in controls*, PDND,
PDD and DLB. Box-and-whisker plots indicate the full range, interquartile
range and median value in each group. Insoluble pSer129 α-syn levels
were significantly higher in PD groups compared with controls in the
midfrontal region. PDD patients also showed significantly higher levels of
insoluble pSer129 α-syn compared with PDND and DLB in the same region.
All disease groups showed significantly higher levels of insoluble
pSer129 α-syn levels compared with controls in the cingulate region. No
significant difference in insoluble pSer129 α-syn levels were observed in the
parahippocampal cortex and thalamus. Soluble pSer129 α-syn levels were
significantly higher in PD groups compared with controls and DLB in the
midfrontal region. In contrast, soluble pSer129 levels were significantly
higher in controls and DLB compared with PD groups in the parahippocampal
region. *Control n numbers varied in the following assays due to limited tissue
availability (soluble fraction: total α-syn: midfrontal n = 13, cingulate n = 10,
parahippocampal n = 16, thalamus n = 16; pSer129 α-syn: midfrontal n = 5,
cingulate n = 12, parahippocampal n = 14; Aβ42: midfrontal n = 13, cingulate
n =16; Aβ40: midfrontal n = 9, cingulate n = 14, parahippocampal n = 16).Abbreviations
AD: Alzheimer’s disease; ANOVA: analysis of variance; APP: amyloid precursor
protein; Aβ: amyloid-beta; BSA: bovine serum albumin; CKI: casein kinase I;
CKII: casein kinase II; CMV: cytomegalovirus; DLB: dementia with Lewy bodies;
EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent
assay; GuHCl: guanidinium chloride; HRP: horseradish peroxidase;
MMSE: mini-mental state examination; PBS: phosphate-buffered saline;
PD: Parkinson’s disease; PDD: Parkinson’s disease with dementia;
PDND: Parkinson’s disease without dementia; pSer129 α-syn: alpha-synuclein
phosphorylated at serine 129; QSBB: Queen Square Brain Bank; RT: room
temperature; Ser129: serine 129; SWDBB: South West Dementia Brain Bank;
TBS: Tris-buffered saline; TBST: Tris-buffered saline with Tween 20; TRIS: tris
(hydroxymethyl)aminomethane; α-syn: alpha-synuclein.Competing interests
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